Key statistics
As of last trade, ACADIA Pharmaceuticals Inc (ACAD:NSQ) traded at 16.46, 16.29% above the 52 week low of 14.15 set on Oct 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.15 |
---|---|
High | 16.69 |
Low | 16.01 |
Bid | 16.45 |
Offer | 16.47 |
Previous close | 16.18 |
Average volume | 1.37m |
---|---|
Shares outstanding | 166.39m |
Free float | 165.48m |
P/E (TTM) | 20.87 |
Market cap | 2.69bn USD |
EPS (TTM) | 0.7753 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 19:40 GMT.
More ▼
- Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
- Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
- Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
- Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
- Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
More ▼